1. Home
  2. TBHC vs RVPH Comparison

TBHC vs RVPH Comparison

Compare TBHC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TBHC

The Brand House Collective Inc.

HOLD

Current Price

$1.00

Market Cap

26.5M

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.22

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBHC
RVPH
Founded
1966
2006
Country
United States
United States
Employees
N/A
14
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
29.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBHC
RVPH
Price
$1.00
$0.22
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$3.14
AVG Volume (30 Days)
90.1K
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$0.20
52 Week High
$2.40
$1.35

Technical Indicators

Market Signals
Indicator
TBHC
RVPH
Relative Strength Index (RSI) 39.00 33.58
Support Level $0.98 N/A
Resistance Level $1.29 $0.31
Average True Range (ATR) 0.07 0.02
MACD 0.01 0.00
Stochastic Oscillator 8.04 30.32

Price Performance

Historical Comparison
TBHC
RVPH

About TBHC The Brand House Collective Inc.

The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: